- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02369471
A Study of GWP42006 in People With Focal Seizures - Part A
A Double Blind, Randomized, Placebo-controlled, Two-part Study to Investigate the Pharmacokinetics, Followed by Efficacy and Safety of GWP42006 as add-on Therapy in Patients With Inadequately Controlled Focal Seizures.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a double blind, randomized, placebo controlled, two-part study. Part A only will be described in this record.
Subjects who satisfy all inclusion and none of the exclusion criteria will begin a 14-day baseline observation period followed by a 14-day treatment period. Subjects will be required to attend six study visits. A follow-up phone call will take place four weeks after last dose.
Part A will enroll three groups of 10 subjects:
- Group 1 - subjects on inducer AEDs (and not on inhibitor AEDs)
- Group 2 - subjects on inhibitor AEDs (and not on inducer AEDs)
- Group 3 - subjects on AEDs that are neither inducers nor inhibitors.
In each of the three groups subjects will be randomized to receive, in a 4:1 ratio, GWP42006 400 mg twice daily or matching placebo. Pharmacokinetic (PK) profiles for GWP42006 and metabolites will be collected on the first and last day of treatment. Samples will also be collected 24h and 72h after the last day of treatment.
Subjects will be required to record a daily diary with information about their seizures, investigational medicinal product (IMP) and concomitant AED administration.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Havířov, Czechia
-
Hradec Králové, Czechia
-
Rychnov nad Kněžnou, Czechia
-
-
-
-
-
Barcelona, Spain
-
-
-
-
-
Birmingham, United Kingdom
-
Dundee, United Kingdom
-
Glasgow, United Kingdom
-
Great Yarmouth, United Kingdom
-
Stoke-on-Trent, United Kingdom
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
For inclusion in Part A of the study patients must fulfil ALL of the following criteria:
- Male or female aged between 18 and 65 years, inclusive.
- Well-documented history of focal epilepsy, with focal seizures as the primary seizure type, compatible electroencephalogram and clinical history.
- Documented computerized tomography / magnetic resonance imaging that shows no progressive neurologic abnormality.
- Has focal seizures despite prior treatment with at least two AEDs (whether as monotherapies or in combination).
Currently treated with one to three AEDs as follows:
- Group 1 - subjects on inducer AEDs (and not on inhibitor AEDs)
- Group 2 - subjects on inhibitor AEDs (and no on inducer AEDs)
- Group 3 - subjects on AEDs that are neither inducers nor inhibitors.
- All medications or interventions for epilepsy (including ketogenic diet and any neurostimulation devices for epilepsy) must have been stable for two weeks prior to screening and the patient is willing to maintain a stable regimen throughout the study.
- Subject is willing to keep any factors expected to affect seizures stable (such as the level of alcohol consumption and smoking).
The patient may not enter Part A of the study if ANY of the following apply:
- Time of onset of epilepsy treatment is less than two years prior to enrolment.
- Episode(s) of status epilepticus during one year prior to screening.
- History of pseudo-seizures.
- Subject has clinically significant unstable medical conditions other than epilepsy.
- Subject has an illness in the four weeks prior to screening or randomization, other than epilepsy, which in the opinion of the investigator would affect seizure frequency.
- Subject has significantly impaired hepatic function at Visit 1.
- Active suicidal plan/intent in the past six months, or a history of suicide attempt in the last two years, or more than one lifetime suicide attempt.
- Subject is currently using or has in the past used recreational or medicinal cannabis, or cannabinoid based medications within the three months prior to screening and is unwilling to abstain for the duration for the study.
- Subject has taken St John's Wort in the last two weeks and/or is unwilling to abstain throughout the study.
- Subject has consumed grapefruit or grapefruit juice three days prior to randomization and/or unwilling to abstain in the three days prior to Visits A2 and A4.
- Any known or suspected hypersensitivity to cannabinoids, sesame oil or any of the excipients of the IMP(s).
- Subjects who have received an IMP within the 12 weeks prior to the screening visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1a
Subjects on inducer AEDs will administer GWP42006.
|
Other Names:
|
Active Comparator: Group 2a
Subjects on inhibitor AEDs will administer GWP42006.
|
Other Names:
|
Experimental: Group 3a
Subjects on AEDs that are neither inducers nor inhibitors will administer GWP42006.
|
Other Names:
|
Placebo Comparator: Group 1b
Matching placebo control for Group 1a.
|
|
Placebo Comparator: Group 2b
Matching placebo control for Group 2a.
|
|
Placebo Comparator: Group 3b
Matching placebo control for Group 3a.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic parameters of GWP42006 and metabolites: Cmax, Cmin, tmax, AUC(0-t), AUC(0-inf) and t1/2, in the presence of other AEDs.
Time Frame: Day 1 to Day 18
|
Day 1 to Day 18
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability of GWP42006 (incidence of adverse events).
Time Frame: Day -14 to Day 43
|
Day -14 to Day 43
|
The plasma concentration of concomitant AEDs.
Time Frame: Day 1 and Day 15
|
Day 1 and Day 15
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Josemir W Sander, MD PhD FRCP, NIRH University College London
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GWEP1330 Part A
- 2014-002594-11 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States